melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Therapeutic Areas
Safety Assessment
 


theraTRACE

Melior Pharmaceuticals

              

 

             

 

                 

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery psychiatric

Open-Field Activity
The open-field test is a useful tool for assessing locomotor, psychological and other sensorimotor behavior in rodents. An automated system is in place that is capable of monitoring multiple locomotor and psychotherapeutic related parameters. Open-field assessments are useful for determining how a drug affects not only normal locomotion but other activities including exploratory behavior, stereotypic activity, rearing, and time spent in pre-defined zones within the chamber. The chamber can be modified to examine anxiety-related behaviors, learning and memory functions, and place-preference assays for addiction. Like the Irwin Observational Battery of tests, this assay can be used in conjunction, and control for behavioral activities, with many of the assays within the Melior theraTRACE® platform. 

Part I: MK-801 induced hyperactivity

 

open field locomotor activity MK-801 stimulated

 

Ambulatory Activity in habituated CD-1 male mice.  MK-801 induced hyperactivity and significantly increased ambulatory counts in 0.178 and 0.32 mg/kg treated mice across time.  Data are mean values; *p<0.05, **p<0.01, ****p<0.0001. 

 

Open field locomotor activity distance traveled and ambulatory counts in MK-801 stimulated mice

Total distance traveled and ambulatory counts in habituated CD-1 male mice.  MK-801 significantly increased total distance traveled and ambulatory counts in 0.178 and 0.32 mg/kg treated mice.  Data are mean values; *p<0.05, ****p<0.0001. 

 

Part II: Risperidone Antagonism of MK-801 induced hyperactivity

 

Open field locomotor activity risperidone and mk-801 induced hyperactivity

 

Ambulatory activity in habituated CD-1 male mice.  Risperidone significantly attenuated MK-801 induced hyperactivity and ambulatory counts in MK-801 challenged mice.  Data are mean values; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 

 

open field activity risperidone and mk-801 induced hyperactivity

 

Total distance traveled and ambulatory counts in habituated CD-1 mice.  Vehicle 1/ MK-801 treated mice exhibited hyperactivity in increased distance traveled and ambulatory counts.  Risperidone (0.032 and 0.1 mg/kg)/ MK-801 treated mice exhibited significantly attenuated distance traveled and ambulatory counts, similar to Vehicle 1/ Vehicle 2 treated mice.  Data are mean ± SEM;   ***p<0.0001, ****p<0.0001 compared to Vehicle 1/ MK-801. 

 

If you are interested in learning more about Open-Field Activity, please contact models@meliordiscovery.com to start the conversation.